Cargando…

纳米药物联合CAR-T疗法在实体肿瘤治疗中的研究进展

Chimeric antigen receptor T cell (CAR-T) therapy has shown remarkable success in treating hematological malignancies. However, CAR-T therapy for solid tumors is still limited due to the unique solid-tumor microenvironment and heterogeneous target antigen expression, which leads to an urgent need of...

Descripción completa

Detalles Bibliográficos
Autores principales: LIU, Yi, LI, Ning, JIANG, Wenyang, GENG, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial board of Chinese Journal of Lung Cancer 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987048/
https://www.ncbi.nlm.nih.gov/pubmed/36792082
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.02
_version_ 1784901295409201152
author LIU, Yi
LI, Ning
JIANG, Wenyang
GENG, Qing
author_facet LIU, Yi
LI, Ning
JIANG, Wenyang
GENG, Qing
author_sort LIU, Yi
collection PubMed
description Chimeric antigen receptor T cell (CAR-T) therapy has shown remarkable success in treating hematological malignancies. However, CAR-T therapy for solid tumors is still limited due to the unique solid-tumor microenvironment and heterogeneous target antigen expression, which leads to an urgent need of combining other therapies. At present, nano delivery system has become one of the most promising directions for the development of anti-tumor drugs. Based on the background of CAR-T and tumor treatment, we focus on the research progress of nanomedicine combined with CAR-T therapy, and systematically review the strategies and examples in recent years in the aspects of in vivo delivery of mRNA, regulation of tumor microenvironment, combination with photothermal therapy. And we also look forward to the future direction of this filed.
format Online
Article
Text
id pubmed-9987048
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Editorial board of Chinese Journal of Lung Cancer
record_format MEDLINE/PubMed
spelling pubmed-99870482023-03-07 纳米药物联合CAR-T疗法在实体肿瘤治疗中的研究进展 LIU, Yi LI, Ning JIANG, Wenyang GENG, Qing Zhongguo Fei Ai Za Zhi Review Chimeric antigen receptor T cell (CAR-T) therapy has shown remarkable success in treating hematological malignancies. However, CAR-T therapy for solid tumors is still limited due to the unique solid-tumor microenvironment and heterogeneous target antigen expression, which leads to an urgent need of combining other therapies. At present, nano delivery system has become one of the most promising directions for the development of anti-tumor drugs. Based on the background of CAR-T and tumor treatment, we focus on the research progress of nanomedicine combined with CAR-T therapy, and systematically review the strategies and examples in recent years in the aspects of in vivo delivery of mRNA, regulation of tumor microenvironment, combination with photothermal therapy. And we also look forward to the future direction of this filed. Editorial board of Chinese Journal of Lung Cancer 2023-01-20 /pmc/articles/PMC9987048/ /pubmed/36792082 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.02 Text en https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle Review
LIU, Yi
LI, Ning
JIANG, Wenyang
GENG, Qing
纳米药物联合CAR-T疗法在实体肿瘤治疗中的研究进展
title 纳米药物联合CAR-T疗法在实体肿瘤治疗中的研究进展
title_full 纳米药物联合CAR-T疗法在实体肿瘤治疗中的研究进展
title_fullStr 纳米药物联合CAR-T疗法在实体肿瘤治疗中的研究进展
title_full_unstemmed 纳米药物联合CAR-T疗法在实体肿瘤治疗中的研究进展
title_short 纳米药物联合CAR-T疗法在实体肿瘤治疗中的研究进展
title_sort 纳米药物联合car-t疗法在实体肿瘤治疗中的研究进展
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987048/
https://www.ncbi.nlm.nih.gov/pubmed/36792082
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.02
work_keys_str_mv AT liuyi nàmǐyàowùliánhécartliáofǎzàishítǐzhǒngliúzhìliáozhōngdeyánjiūjìnzhǎn
AT lining nàmǐyàowùliánhécartliáofǎzàishítǐzhǒngliúzhìliáozhōngdeyánjiūjìnzhǎn
AT jiangwenyang nàmǐyàowùliánhécartliáofǎzàishítǐzhǒngliúzhìliáozhōngdeyánjiūjìnzhǎn
AT gengqing nàmǐyàowùliánhécartliáofǎzàishítǐzhǒngliúzhìliáozhōngdeyánjiūjìnzhǎn